Severin Investments LLC Has $497,000 Position in CVS Health Corporation $CVS

Severin Investments LLC lessened its stake in CVS Health Corporation (NYSE:CVS) by 52.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,916 shares of the pharmacy operator’s stock after selling 7,705 shares during the period. Severin Investments LLC’s holdings in CVS Health were worth $497,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CVS. Swiss RE Ltd. acquired a new position in CVS Health during the 4th quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the period. Sankala Group LLC bought a new stake in shares of CVS Health during the fourth quarter worth approximately $28,000. Mcguire Capital Advisors Inc. acquired a new position in CVS Health in the fourth quarter valued at approximately $28,000. Finally, Ares Financial Consulting LLC acquired a new position in CVS Health in the fourth quarter valued at approximately $29,000. 80.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on CVS shares. TD Cowen lifted their target price on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. UBS Group increased their price target on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Mizuho lifted their price objective on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $101.28.

Insider Activity

In other news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health has been featured in articles highlighting its strong fundamentals and recent move to a fresh 52-week high, suggesting investors still see room for upside if earnings and guidance remain solid.
• Positive Sentiment: The company’s marketing and brand-building efforts tied to America250 are reinforcing CVS Health’s public-facing profile, which may help support broader consumer engagement and brand strength.
• Neutral Sentiment: CVS Health also published health-screening content aimed at encouraging preventive care, which is positive for brand awareness but unlikely to move the stock on its own.
• Neutral Sentiment: A Wall Street Zen downgrade to Hold adds a cautious note, but it does not appear to be a major driver compared with the stock’s recent strength.
• Negative Sentiment: Florida has opened a probe into CVS Health over alleged pharmacy steering, raising the risk of regulatory scrutiny, possible legal costs, and renewed investor concern about pharmacy benefit manager practices. Florida probes CVS Health over alleged pharmacy steering
• Negative Sentiment: Industry coverage noting that UnitedHealth, Humana, and CVS have denied some post-hospital care at high rates could keep attention on utilization management and reimbursement practices, which may pressure sentiment around managed-care and pharmacy operations.

CVS Health Trading Up 0.0%

CVS opened at $103.59 on Wednesday. The firm’s fifty day moving average is $92.88 and its two-hundred day moving average is $82.79. The firm has a market cap of $132.17 billion, a PE ratio of 45.63, a price-to-earnings-growth ratio of 1.01 and a beta of 0.62. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $106.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.